Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

San Diego's Denovo Biopharma Opens Doors to New R&D Center, Names New CMO and CFO

  • Post author:Sam
  • Post published:January 2, 2018
  • Post category:BioPharma

The new 7600 square feet custom-built, state-of-the-art facility hosts Denovo's biomarker discovery platform, US clinical team and serves as Denovo's US headquarters. Source: BioSpace

Continue ReadingSan Diego's Denovo Biopharma Opens Doors to New R&D Center, Names New CMO and CFO

What You Need to Know About BlueRock Therapeutics

  • Post author:Sam
  • Post published:January 2, 2018
  • Post category:BioPharma

BlueRock Therapeutics, which has locations in Toronto, NYC and Cambridge, Mass., rocketed to existence in December 2016 with $225M in venture funding to focus on regenerative medicine, using iPSC therapies.…

Continue ReadingWhat You Need to Know About BlueRock Therapeutics

New SoCal Biotech Launches With $55.3M Backed by Novartis, Sanofi and 5AM Ventures

  • Post author:Sam
  • Post published:January 2, 2018
  • Post category:BioPharma

The round was co-led by 5AM Ventures, Kleiner Perkins, Novartis Venture Fund, and Sanofi Ventures. Source: BioSpace

Continue ReadingNew SoCal Biotech Launches With $55.3M Backed by Novartis, Sanofi and 5AM Ventures

Drum Roll, Please…Introducing The 2018 Life Sciences Hotbeds

  • Post author:Sam
  • Post published:January 2, 2018
  • Post category:BioPharma

The annual Hotbed Maps have guided professionals in their career paths all across the country and abroad. Source: BioSpace

Continue ReadingDrum Roll, Please…Introducing The 2018 Life Sciences Hotbeds

Biotech Startup Elstar Therapeutics Closes $39M for New Immunotherapy Approach

  • Post author:Sam
  • Post published:January 2, 2018
  • Post category:BioPharma

The funds will be used to expand its growing pipeline and progress several early stage molecules towards the clinic. Source: BioSpace

Continue ReadingBiotech Startup Elstar Therapeutics Closes $39M for New Immunotherapy Approach

Sangamo, Pfizer Deepen Relationship With New $162M ALS R&D Pact

  • Post author:Sam
  • Post published:January 2, 2018
  • Post category:BioPharma

Sangamo and Pfizer will use the company's ZFP-TFs to develop the treatments that are linked to mutations of the C9ORF72 gene, which can cause both ALS and FTLD. Source: BioSpace

Continue ReadingSangamo, Pfizer Deepen Relationship With New $162M ALS R&D Pact

Spark's Blindness-Curing Gene Therapy Comes With a $850,000 Price Tag

  • Post author:Sam
  • Post published:January 2, 2018
  • Post category:BioPharma

The therapy is the first type approved by the FDA that targets a disease caused by mutations in a specific gene. Source: BioSpace

Continue ReadingSpark's Blindness-Curing Gene Therapy Comes With a $850,000 Price Tag

Celgene Co-Founder Bags $23M for Johns Hopkins Spinout NexImmune

  • Post author:Sam
  • Post published:January 1, 2018
  • Post category:BioPharma

In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune’s Board of Directors. Source: BioSpace

Continue ReadingCelgene Co-Founder Bags $23M for Johns Hopkins Spinout NexImmune

Top 20 Life Science Startups to Watch in 2018

  • Post author:Sam
  • Post published:January 1, 2018
  • Post category:BioPharma

BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2016. Source: BioSpace

Continue ReadingTop 20 Life Science Startups to Watch in 2018

Massachusetts Selecta Biosciences' CEO to Retire at the End of 2018

  • Post author:Sam
  • Post published:January 1, 2018
  • Post category:BioPharma

Werner Cautreels, Ph.D., intends to retire effective December 31, 2018. Source: BioSpace

Continue ReadingMassachusetts Selecta Biosciences' CEO to Retire at the End of 2018
  • Go to the previous page
  • 1
  • …
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 288
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.